A Phase 3 interventional study of Vonoprazan and Amoxicillin in Helicobacter Pylori Infection, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 153 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-05.
Sponsored by Phathom Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.
Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant has at least one of the following clinical conditions with confirmed HP+ infection demonstrated by a positive 13C-UBT during the Screening Period.
Exclusion Criteria:
The participant has any of the following abnormal laboratory test values at the start of the Screening Period:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.
Drug: Vonoprazan · Drug: Amoxicillin
Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.
Drug: Vonoprazan · Drug: Amoxicillin · Drug: Clarithromycin
Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.
Drug: Amoxicillin · Drug: Clarithromycin · Drug: Lansoprazole
Over-encapsulated tablets administered orally.
Capsules administered orally.
Tablets administered orally.
Over-encapsulated capsules administered orally.
Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H Pylori at Baseline
H pylori eradication was determined by the \^13C-UBT test.
Time frame: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants With a Clarithromycin-resistant Strain of H Pylori at Baseline
H pylori eradication was determined by the \^13C-UBT test.
Time frame: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
Percentage of All Participants With Successful Helicobacter Pylori (H Pylori) Eradication
H pylori eradication was determined by the \^13C-UBT test.
Time frame: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
1046 participants were randomized at 103 study sites, including 71 in the United States and 32 in Europe.
| Milestone | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy |
|---|---|---|---|
| Started | 349 | 349 | 348 |
| Received study drugs | 348 | 346 | 345 |
| Completed | 334 | 331 | 334 |
| Not completed | 15 | 18 | 14 |
| Withdrew: Pretreatment event, adverse event, or serious adverse event | 1 | 7 | 4 |
| Withdrew: Significant protocol deviation | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 3 |
| Withdrew: Voluntary withdrawal | 0 | 1 | 1 |
| Withdrew: Withdrawal of consent | 4 | 1 | 3 |
| Withdrew: Miscellaneous | 7 | 5 | 3 |
H pylori eradication was determined by the \^13C-UBT test.
| percentage of participants | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy |
|---|---|---|---|
| Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H Pylori at Baseline | 78.5 | 84.7 | 78.8 |
H pylori eradication was determined by the \^13C-UBT test.
| percentage of participants | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy |
|---|---|---|---|
| Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants With a Clarithromycin-resistant Strain of H Pylori at Baseline | 69.6 | 65.8 | 31.9 |
H pylori eradication was determined by the \^13C-UBT test.
| percentage of participants | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy |
|---|---|---|---|
| Percentage of All Participants With Successful Helicobacter Pylori (H Pylori) Eradication | 77.2 | 80.8 | 68.5 |
Collected over Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vonoprazan Dual Therapy | 0/348 (0%) | 5/348 (1.4%) | 20/348 (5.7%) |
| Vonoprazan Triple Therapy | 2/346 (0.6%) | 6/346 (1.7%) | 27/346 (7.8%) |
| Lansoprazole Triple Therapy | 1/345 (0.3%) | 3/345 (0.9%) | 48/345 (13.9%) |
| Event | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy |
|---|---|---|---|
| Pneumonia viralInfections and infestations | 0/348 | 0/346 | 1/345 |
| Cholecystitis acuteHepatobiliary disorders | 0/348 | 0/346 | 1/345 |
| Peripheral ischaemiaVascular disorders | 0/348 | 0/346 | 1/345 |
| Cardiac arrestCardiac disorders | 0/348 | 1/346 | 0/345 |
| Coronary artery occlusionCardiac disorders | 0/348 | 1/346 | 0/345 |
| Corona virus infectionInfections and infestations | 1/348 | 1/346 | 0/345 |
| Duodenal polypGastrointestinal disorders | 0/348 | 1/346 | 0/345 |
| Jaw fractureInjury, poisoning and procedural complications | 0/348 | 1/346 | 0/345 |
| Spinal painMusculoskeletal and connective tissue disorders | 0/348 | 1/346 | 0/345 |
| Atrial fibrillationCardiac disorders | 1/348 | 0/346 | 0/345 |
| Event | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 18/348 | 14/346 | 33/345 |
| DysgeusiaNervous system disorders | 2/348 | 15/346 | 21/345 |
Randomized Set - All participants randomly assigned to receive study drug regardless of whether or not they received a dose of study drug during the study.
| Age, Continuous(years) | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy | Total |
|---|---|---|---|---|
| Mean | 51.9 ± 13.47 | 50.7 ± 13.88 | 51.6 ± 13.61 | 51.4 ± 13.65 |
| Sex: Female, Male(Participants) | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy | Total |
|---|---|---|---|---|
| Female | 210 | 226 | 216 | 652 |
| Male | 139 | 123 | 132 | 394 |
| Ethnicity (NIH/OMB)(Participants) | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 95 | 99 | 89 | 283 |
| Not Hispanic or Latino | 251 | 249 | 259 | 759 |
| Unknown or Not Reported | 3 | 1 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Vonoprazan Dual Therapy | Vonoprazan Triple Therapy | Lansoprazole Triple Therapy | Total |
|---|---|---|---|---|
| White | 316 | 307 | 312 | 935 |
| Black or African-American | 22 | 30 | 25 | 77 |
| Asian | 4 | 6 | 6 | 16 |
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Other | 4 | 1 | 3 | 8 |
| Unknown | 1 | 1 | 1 | 3 |
| Not Reported | 1 | 3 | 0 | 4 |
Showing the first 100 of 153 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Mar 2021, 15 months.
Results were first posted in Apr 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vonoprazan · Clarithromycin
Phathom Pharmaceuticals, Inc.